The Supreme Court’s recent unanimous decision on FDA’s drug-approval authority is utterly unremarkable.

Tummy bug testing outfit Genetic Signatures is honing its operations after finding its company-making US expansion was harder ...

With so few Alzheimer's drugs available, repurposing medications approved for other conditions could be the key to tackling ...

With few treatments available to treat Alzheimer’s disease, scientists have turned to cancer drugs as a potential means of ...

UCSF researchers find that two FDA-approved cancer drugs significantly improve memory in Alzheimer’s mouse models and reduce ...

Stanford's George Tidmarsh has authored 143 scientific papers and patents, as well as played a central role in developing ...

A standoff over Elevidys could have major consequences for Duchenne patients, gene therapy companies and the perception of ...

Scientists at UCSF and Gladstone Institutes have identified cancer drugs that promise to reverse the changes that occur in ...

A study comparing the gene expression signature of Alzheimer's disease with those elicited by 1,300 approved drugs found a combination of two cancer medications that could treat the most common form ...

The Food and Drug Administration named a longtime pharmaceutical executive to run the agency’s drug program. Dr.

Food and Drug Administration commissioner Marty Makary has chosen former biotech executive George Tidmarsh as the agency’s ...

An analysis from the Congressional Budget Office warns that cuts to the National Institutes of Health and FDA drug reviews could significantly reduce the number of new medications reaching the U.S.